In­fec­tious dis­ease biotech Blue­jay rais­es $182M for he­pati­tis tri­als

Cal­i­for­nia biotech Blue­jay Ther­a­peu­tics has se­cured a megaround to con­tin­ue de­vel­op­ing its treat­ment can­di­dates for chron­ic he­pati­tis D and B.

The $182 mil­lion Se­ries C …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.